Deal worth up to $1.3 billion brings AI-powered GPCR target discovery into Lilly’s obesity and cardiometabolic pipeline. 2.

Medical cannabis has a high discontinuation rate among patients with chronic musculoskeletal pain, particularly in the first ...

First FDA-approved therapy for non-cystic fibrosis bronchiectasis; addresses a major unmet respiratory need. 2. Phase 3 data ...

Progression-free survival and overall survival were significantly greater in the combination therapy group compared to ...

In this retrospective cohort study, the proportion of chemotherapy episodes delivered by oncology subspecialists in the ...